As per DelveInsight, the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma dynamics are expected to evolve in the market years owing to the increasing incident population, the launch of approved therapies, and the extensive research & development activities of pharmaceutical companies in the therapeutics domain.
DelveInsight’s “Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market Forecast” report provides a comprehensive understanding of current treatment practices, MALT Lymphoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market Assessment and Key Developments
- The MALT Lymphoma market size in the 7MM is expected to change during the study period 2019–2032.
- MALT lymphoma accounts for about 5% of non-Hodgkin lymphoma diagnosed annually. Annual incidence is estimated at 1/313,000 cases.
- DelveInsight’s gender-specific assessment of MALT Lymphoma estimates that females are affected with MALT Lymphoma slightly more than males.
- The incidence of extra-nodal MZBCL of MALT type in western countries is approximately 7% of all NHL diagnosed by histologic examination.
- The launch of the emerging therapies such as Ziv-aflibercept, BKM120 & Rituximab, Rituxan/Bendamustine/PCI-32765, Brentuximab Vedotin + Rituximab, Ixazomib Citrate and Rituximab, Ontuxizumab (MORAb-004), CD22-Targeted CAR-T cells, is expected to create a significant impact on the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma therapeutics market.
- As per DelveInsight’s assessment, there are approx. 8+ key companies which are developing therapies for Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.
- Some of the major pharma companies actively working in the MALT) Lymphoma Market include BeiGene (NASDAQ: BGNE), Incyte (NASDAQ: INCY), Genentech, Sound Biologics, Morphotek, Novartis (NYSE: NVS), Seattle Genetics (NASDAQ: SGEN), Millennium Pharmaceuticals, PersonGen BioTherapeutics, Celldex Therapeutics (NASDAQ: CLDX, Loxo Oncology, Kite Pharma, Bio-Path Holdings (NASDAQ: BPTH, MEI Pharma (NASDAQ: MEIP), Kyowa Kirin (OTCMKTS: KYKOF), MorphoSys (NASDAQ: MOR), Beijing Mabworks Biotech, and others.
- Currently, Morphosys has its Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma drug candidates in the most advanced stage of clinical development.
- In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally. Tafasitamab is being co-commercialized by Incyte and MorphoSys in the United States.
Get more detailed insights @ Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market Trends and Developments
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Disease Overview
Lymphoma is the cancer of the lymphatic system. The lymphatic system is a network of thin tubes and lymph nodes that run throughout the body. Primary gastric lymphoma (PGL) is the most common extranodal site of non-Hodgkin lymphoma and represents 30–40% of all extranodal lymphomas. The frequent histological subtypes of PGL are marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) and diffuse large B-cell lymphoma (DLBCL).
MALT stands for mucosa-associated lymphoid tissue. The mucosa is the moist tissue that lines some organs and body cavities, including the nose, mouth, lungs, and digestive tract; thus, MALT lymphoma starts in the body organs and not in the lymph nodes. Other commonly involved extranodal sites include other parts of the gastrointestinal tract, thyroid, salivary gland, lung, lacrimal gland, synovium, dura mater, breast, skin, and eyes.
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Epidemiology Segmentation
The report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented as –
- Incident cases of MALT Lymphoma
- Incident cases of Gastric MALT Lymphoma
- Gender-specific cases of MALT Lymphoma
- Age-specific cases of MALT Lymphoma
Download the report to understand which factors are driving MALT Lymphoma epidemiology trends @ Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Epidemiological Assessment
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Treatment Market
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma treatment is tailored according to the type, stage, and grade. MALT Lymphoma treatment also depends upon whether the patient has an infection linked to the lymphoma. Most slow-growing, localized MALT lymphomas respond well to treatment. Local therapies such as radiation therapy or surgery are used with early-stage MALT lymphomas that occur in areas other than the stomach. Similarly, surgery is employed sometimes if the lymphoma only affects one part of the body and is in an area where it can be safely removed.
To further improve the treatment scenario, companies all over the globe are persistently working towards the development of new treatment therapies. As per DelveInsight, the extensive research and development activities of pharmaceutical companies, along with the expected launch of approved therapies, will fuel the market’s growth during the forecast period.
Learn how the market will evolve in the coming years @ Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market Forecast
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Therapeutics Assessment
Globally, several key companies are actively working in the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma therapeutics market. Currently, Morphosys has its drug candidates in the most advanced stage of clinical development.
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Key Companies
- BeiGene
- Incyte
- Genentech
- Sound Biologics
- Morphotek
- Novartis
- Seattle Genetics
- Millennium Pharmaceuticals
- PersonGen BioTherapeutics
- Celldex Therapeutics
- Loxo Oncology
- Kite Pharma
- Bio-Path Holdings
- MEI Pharma
- Kyowa Kirin
- MorphoSys
- Beijing Mabworks Biotech
And many others
Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Emerging Drugs
- Tafasitamab: Morphosys
- Zandelisib: MEI Pharma
- Ziv-aflibercept: Regeneron Pharmaceuticals
- Ontuxizumab (MORAb-004): Morphotek
- BKM120 & Rituximab: Kami Maddocks in collaboration with Novartis
- CD22-Targeted CAR-T cells: PersonGen BioTherapeutics (Suzhou)
- Rituxan/Bendamustine/PCI-32765: Kami Maddocks in collaboration with Pharmacyclics LLC
- Brentuximab Vedotin + Rituximab: Northwestern University in collaboration with Seattle Genetics
- Ixazomib Citrate and Rituximab: The University of Washington in collaboration with Millennium Pharmaceuticals
Learn more about the emerging therapies & ongoing clinical trials @ Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Therapeutics Assessment
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market – Report Key Strength
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Companies: BeiGene,Incyte, Genentech, Sound Biologics, Morphotek, Novartis, Seattle Genetics, Millennium Pharmaceuticals, PersonGen BioTherapeutics, Celldex Therapeutics, Loxo Oncology, Kite Pharma, Bio-Path Holdings, MEI Pharma, Kyowa Kirin, MorphoSys, Beijing Mabworks Biotech, and many others
- Therapeutic Assessment: Mucosa-associated Lymphoid Tissue (MALT) Lymphoma marketed and emerging therapies
- Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market Dynamics: Major market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market Access and Reimbursement Scenario
Discover more about key report offerings @ Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market Outlook
Table of Contents
| 1. | Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market Key Insights |
| 2. | Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market Report Introduction |
| 3. | Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market Overview at a Glance |
| 4. | Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Treatment and Management |
| 7. | Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Emerging Drugs |
| 10. | 7 Major Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market Analysis |
| 11. | Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market Outlook |
| 12. | Potential of Current and Emerging Therapies |
| 13. | KOL Views |
| 14. | Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market Drivers |
| 15. | Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market Barriers |
| 16. | Unmet Needs |
| 17. | SWOT Analysis |
| 18. | Appendix |
| 19. | DelveInsight Capabilities |
| 20. | Disclaimer |
| 21. | About DelveInsight |
Download the sample PDF for detailed report offerings @ Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market Assessment
Related Reports by DelveInsight
- Primary Mediastinal Large B-Cell Lymphoma Market
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Market
Other Trending Reports by DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact With Us
Manager (Marketing & IB)
info@delveinsight.com
+1(919)321-6187